AR067997A1 - ORGANIC COMPOUNDS - Google Patents
ORGANIC COMPOUNDSInfo
- Publication number
- AR067997A1 AR067997A1 ARP080103643A ARP080103643A AR067997A1 AR 067997 A1 AR067997 A1 AR 067997A1 AR P080103643 A ARP080103643 A AR P080103643A AR P080103643 A ARP080103643 A AR P080103643A AR 067997 A1 AR067997 A1 AR 067997A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- antagonist
- agonist
- colipid
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a una composicion farmacéutica que comprende: (A) una o más sustancias medicamentosas; (B) un lípido; (C) un colípido; y (D) un mejorador de flujo; en donde el colípido y el mejorador de flujo juntos forman una dispersion liposomal que contiene vesículas lipídicas que encapsulan la una o más sustancias medicamentosas. La composicion farmacéutica opcionalmente se seca para formar una formulacion en polvo seco que tiene flujo suelto y de preferencia es adecuada para administracion por inhalacion o nasal. También se describe un proceso para preparar la composicion y la formulacion en polvo seco. Reivindicacion 2: La composicion de conformidad con la reivindicacion 1 en donde el diámetro promedio de las vesículas lipídicas está entre 70 y 550 nm. Reivindicacion 3: La composicion de conformidad con la reivindicacion 1 o 2, en donde la o cada sustancia medicamentosa es un agonista del adrenoceptor-beta2, un antagonista muscarínico, un glucocorticosteriode, un agonista del receptor de glucocorticoides no esteroide, un agonista de A2a, un antagonista de A2b, un antihistamínico, un inhibidor de caspasa, un antagonista de LTB4, un antagonista de LTD4, un inhibidor de fosfodiesterasa, un mucolitico, un inhibidor de metaloproteinasa de matriz metálica, un antagonista del receptor de leucotrieno, una hormona del crecimiento, heparina, estradiol, un antagonista de prostaglandina D2, un antagonista del receptor de CRTH2, cromoglicato de sodio, un inhibidor de la síntesis de IgE un antibiotico, un interferon, un inhibidor del canal de potasio, un inmunomodulador, un agente citostático, un inhibidor de elastasa, un antineoplásico, un inhibidor de prostatina, un péptido, un oIigonucleotido ARN (tal como ARNic), ADN, un plásmido, insulina, una interleucina, GLP-1, un agente antineoplásico, o un anticuerpo.This refers to a pharmaceutical composition comprising: (A) one or more medicinal substances; (B) a lipid; (C) a colipid; and (D) a flow improver; wherein the colipid and the flow improver together form a liposomal dispersion containing lipid vesicles that encapsulate the one or more drug substances. The pharmaceutical composition is optionally dried to form a dry powder formulation that has loose flow and is preferably suitable for inhalation or nasal administration. A process for preparing the composition and dry powder formulation is also described. Claim 2: The composition according to claim 1 wherein the average diameter of the lipid vesicles is between 70 and 550 nm. Claim 3: The composition according to claim 1 or 2, wherein the or each drug substance is an adrenoceptor-beta2 agonist, a muscarinic antagonist, a glucocorticosteriode, a non-steroidal glucocorticoid receptor agonist, an A2a agonist, an A2b antagonist, an antihistamine, a caspase inhibitor, an LTB4 antagonist, an LTD4 antagonist, a phosphodiesterase inhibitor, a mucolytic, a metal matrix metalloproteinase inhibitor, a leukotriene receptor antagonist, a growth hormone , heparin, estradiol, a prostaglandin D2 antagonist, a CRTH2 receptor antagonist, sodium cromoglycate, an inhibitor of IgE synthesis an antibiotic, an interferon, a potassium channel inhibitor, an immunomodulator, a cytostatic agent, a elastase inhibitor, an antineoplastic, a prostatin inhibitor, a peptide, an RNA oligonucleotide (such as siRNA), DNA, a plasmid, insu lina, an interleukin, GLP-1, an antineoplastic agent, or an antibody.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114981 | 2007-08-24 | ||
| EP07123163 | 2007-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067997A1 true AR067997A1 (en) | 2009-10-28 |
Family
ID=40149638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103643A AR067997A1 (en) | 2007-08-24 | 2008-08-21 | ORGANIC COMPOUNDS |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR067997A1 (en) |
| CL (1) | CL2008002479A1 (en) |
| PE (1) | PE20090607A1 (en) |
| TW (1) | TW200916126A (en) |
| WO (1) | WO2009027337A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014MN00380A (en) | 2006-06-30 | 2015-06-19 | Iceutica Pty Ltd | |
| AP2015008955A0 (en) | 2009-04-24 | 2015-12-31 | Icuetica Pty Ltd | A novel formulation of indomethacin |
| WO2013009928A1 (en) | 2011-07-11 | 2013-01-17 | Organic Medical Research | Cannabinoid formulations |
| KR102240042B1 (en) * | 2012-05-03 | 2021-04-14 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| WO2018160295A1 (en) * | 2017-01-25 | 2018-09-07 | Yiannios James John | Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| US11266649B2 (en) | 2018-02-01 | 2022-03-08 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations |
| EP3520782A3 (en) * | 2018-02-01 | 2019-11-13 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations containing adenosine a2a receptor antagonists |
| WO2020102394A1 (en) * | 2018-11-13 | 2020-05-22 | Civitas Therapeutics, Inc. | Respirable polynucleotide powder formulations for inhalation |
| US10729687B1 (en) * | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| WO2021004524A1 (en) * | 2019-07-10 | 2021-01-14 | The University Of Hong Kong | PEGylated synthetic KL4 peptide, Compositions and Methods Thereof |
| CN114209651A (en) * | 2021-11-18 | 2022-03-22 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefotaxime sodium compound and preparation method thereof |
| CN114053226A (en) * | 2021-11-18 | 2022-02-18 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefminox sodium compound and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004787A1 (en) * | 1995-08-01 | 1997-02-13 | Novartis Ag | Liposomal oligonucleotide compositions |
| EP2664672A1 (en) * | 2003-04-17 | 2013-11-20 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| WO2005011632A1 (en) * | 2003-08-01 | 2005-02-10 | National Institute Of Advanced Industrial Science And Technology | Target-directed and enteric absorption-controlled liposome having sugar chain and cancer remedy and diagnostic containing the same |
| WO2005105152A2 (en) * | 2004-05-05 | 2005-11-10 | Atugen Ag | Lipids, lipid complexes and use thereof |
| GB0418172D0 (en) * | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
| EP1842558B1 (en) * | 2005-01-28 | 2012-06-13 | Kyowa Hakko Kirin Co., Ltd. | Composition for inhibiting expression of target gene |
| US20070172430A1 (en) * | 2006-01-20 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Dry powder compositions for rna influenza therapeutics |
| WO2007121947A1 (en) * | 2006-04-20 | 2007-11-01 | Silence Therapeutics Ag. | Lipoplex formulations for specific delivery to vascular endothelium |
| GB0608838D0 (en) * | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
-
2008
- 2008-08-21 AR ARP080103643A patent/AR067997A1/en unknown
- 2008-08-22 TW TW097132233A patent/TW200916126A/en unknown
- 2008-08-22 WO PCT/EP2008/061018 patent/WO2009027337A1/en active Application Filing
- 2008-08-22 PE PE2008001429A patent/PE20090607A1/en not_active Application Discontinuation
- 2008-08-22 CL CL2008002479A patent/CL2008002479A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20090607A1 (en) | 2009-06-11 |
| TW200916126A (en) | 2009-04-16 |
| CL2008002479A1 (en) | 2009-05-08 |
| WO2009027337A1 (en) | 2009-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067997A1 (en) | ORGANIC COMPOUNDS | |
| US11660307B2 (en) | Methods for treating SARS CoV-2 infections | |
| ES2940259T3 (en) | Compound and compositions for intracellular delivery of therapeutic agents | |
| AR124140A2 (en) | ANTIBODY FORMULATIONS | |
| CL2019000209A1 (en) | Novel orally administrable formulation. | |
| WO2007040469A3 (en) | Chloroquine coupled compositions and methods for their synthesis | |
| US20230124862A1 (en) | Bismuth thiol compounds and compositions and methods of treating microbial co-infections | |
| AR086249A1 (en) | COMPOSITIONS OF VAGINAL ADMINISTRATION FAST DISSOLUTION TABLETS | |
| CL2011000653A1 (en) | Compounds derived from 1-amino-2-cyclobutyl-ethyl-boronic acid; pharmaceutical composition; lyophilized powder and method to obtain it; and use in the treatment of cancer. | |
| CL2009000662A1 (en) | Trisubstituted 1,2,4-triazole derivative compounds, modulators of the nicotinic acetylcholine receptor; pharmaceutical composition; its preparation process; and use for the prevention or treatment of psychotic disorders, intellectual impairment disorders or diseases, or inflammatory diseases or disorders. | |
| GT200500155A (en) | PLATINUM-RESISTANT CANCER THERAPY | |
| MX2010006284A (en) | Phenylephrine pharmaceutical formulations and compositions for transmucosal absorption. | |
| BRPI0818324B8 (en) | liquid formulation containing luteinizing hormone (LH) or a variant thereof, its use, its form of presentation, process for its preparation and pharmaceutical composition | |
| Monti et al. | Poloxamer 407 microspheres for orotransmucosal drug delivery. Part II: In vitro/in vivo evaluation | |
| MXPA06011467A (en) | Active substance combination comprising a carbinol combined to at least an nsaid. | |
| CR9468A (en) | OBLEA CONTAINING STEROID HORMONES | |
| AR051589A1 (en) | THERAPEUTIC AGENTS | |
| AR095159A2 (en) | A PHARMACEUTICAL COMPOSITION IN THE FORM OF A CAPSULE FOR ORAL ADMINISTRATION | |
| AR055953A1 (en) | SUBEROILANILIDE HYDROXAMIC ACID FORMULATIONS AND PROCEDURES FOR THE PRODUCTION OF THE SAME | |
| PE20050488A1 (en) | INDIVIDUALLY DOSED, CHEWABLE, NON-COMPRESSED FORMS OF ADMINISTRATION | |
| KR20220108770A (en) | Auricular formulations for drug-induced ototoxicity | |
| UY30241A1 (en) | DOSING AEROSOLS FOR THE ADMINISTRATION OF PHARMACEUTICAL PREPARATIONS | |
| MY154770A (en) | Production process for nsaid-containing lozenges, their compositions, their medicinal use | |
| EA201070626A1 (en) | DELIVERY SYSTEM OF MEDICINES FOR THE INTRODUCTION OF WATER-SOLUBLE CATION AND AMFILA PHARMACEUTICAL ACTIVE SUBSTANCE | |
| US20070207977A1 (en) | Naphthalimide compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |